A study of clinicopathological profile and treatment outcomes in patients with autoimmune hemolytic anaemia
DOI:
https://doi.org/10.18203/2349-3933.ijam20190542Keywords:
AIHA, DAT, Haemolytic anaemia, Primary AIHA, Secondary AIHA, SLEAbstract
Background: Autoimmune haemolytic anaemia (AIHA) is relatively uncommon condition with grave consequences, if not diagnosed and treated early. The literature on the clinical outcome and response to treatment is relatively scarce. Aim was to study the clinic-pathological profile and the treatment outcomes in patients with AIHA.
Methods: Around 25 patients with AIHA attending a tertiary care hospital over a period of one year were included in the study. The patients were divided based on severity of anaemia and etiology. All the patients data were analysed for the demographic data, clinico -pathological findings and the response to treatment. All the patients data were analysed using SPSS software (version 22).
Results: Out of 25 patients, 76% were females and 24% were males. Based on severity of anaemia, 60%, 28% and 8% had severe, moderate and mild anaemia. Around 48% of the patients had thrombocytopenia along with anaemia. 8 (32%) and 17 (68%) patients have primary and secondary AIHAs respectively. In our study the commonest cause for the secondary AIHA was Systemic Lupus Erythematosus (SLE) followed by haematological malignancy, primary Sjogrens, Anti-phospholipid antibody (APLA) syndrome, carcinoma colon and Wilsons disease. Hepatosplenomegaly and lymphadenopathy were present in 36% and 4% respectively. Out of 22 (88%) patients on corticosteroid therapy, 15 (60%) patients responded to corticosteroids alone and 6(24%) patients required corticosteroid plus immunosuppressive therapy.
Conclusions: AIHA has to be ruled out in all anaemia patients with indirect hyperbilirubinemia and abnormal peripheral smear. Secondary AIHA is more common than primary. Corticosteroids and immunosuppressive agents are the mainstay of treatment of AIHA.
References
Raghuveer P, Renjitha B, Veena S, Rema G, Neeraj S. Clinical characteristics and treatment outcomes of primary autoimmune hemolyticanemia: a single center study from South India. Blood Res. 2016;51:88-94.
Sudulagunta SR, Kumbhat M, Sodalagunta MB, Nataraju AS, Raja SK, Thejaswi KC, et al. Warm Autoimmune Hemolytic Anemia: Clinical Profile and Management. J Hematol. 2017 Mar 21;6(1):12-20.
Packman CH. The clinical pictures of autoimmune hemolytic anemia. Transfus Med Hemother. 2015;42:317-24.
Allgood JW, Chaplin H, Jr. Idiopathic acquired autoimmune hemolytic anemia. A review of forty-seven cases treated from 1955 through 1965. Am J Med. 1967;43(2):254-73.
Aladjidi N, Leverger G, Leblanc T, Picat MQ, Michel G, Bertrand Y, et al. New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children. Haematologica. 2011;96:655-63.
Zulfiqar AA, Mahdi R, Mourot-Cottet R, Pennaforte JL, Novella JL, Andrès E. Autoimmune hemolytic anemia-a short review of the literature, with a focus on elderly patients. J Hematol Thrombo Dis. 2015;3:228.
Michel M, Chanet V, Dechartres A, Morin AS, Piette JC, Cirasino L, et al. The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood. 2009 Oct 8;114(15):3167-72.
Zupanska B, Sylwestrowicz T, Pawelski S. The results of prolonged treatment of autoimmune haemolytic anaemia. Haematologia (Budap). 1981;14(4):425-33.
Petz LD. Treatment of autoimmune hemolytic anemias. Curr Opin Hematol. 2001;8(6):411-6.
Thomson EL, Dennis JJ. A Burkholderia cepacia complex non-ribosomal peptide-synthesized toxin is hemolytic and required for full virulence. Virulence. 2012 May 1;3(3):286-98.
Hutchison ML, Poxton IR, Govan JR. Burkholderia cepacia produces a hemolysin that is capable of inducing apoptosis and degranulation of mammalian phagocytes. Infect Immun. 1998;66:2033-9.
